How does the operation of PHARMAC's 'Community Exceptional ...

Marshall, C., & Rossman, B. B. (1999). Designing qualitative research (3rd ed.).
Thousand Oaks, London, New Delhi: Sage Productions p. 29
Mays, N., & Smith, J. (2005). Health System reform in England since 1997: To
Market to Market? Paper presented at the 17/02/2005, Victoria University
of Wellington.
McKee, J., & Figueras, J. (1996). For Debate: Setting priorities: can Britain learn
from Sweden? . British Medical Journal, 312 (16 March), 691-694.
McNaughton, H., Kayes, N., & McPherson, K. (2006). Interferon beta,
PHARMAC, and political directives: in the best interests of people with
multiple sclerosis? New Zealand Medical Journal, 119(1232).
McPhee, S., Hodges, L. D., Wright, P. F. A., Wynne, P. M., Kalifatus, N.,
Harney, D. W., & Macrides, T. A. (2006). Anti-cyclooeygenase effects of
lipid extracts from the New Zealand green-lipped mussel, Perna
canaliculus. Comparative Biochemestry and Physiology, 146(Part B),
346-356. doi: 17197217
McSoriley, J. (2000). Bills Digest, NZ Public Health and Disability Bill 2000 Bills
Digest number 681. Wellington: New Zealand Parliamentary Library.
Menkes D. (2000). New Zealand's pharmaceutical reference-pricing strategy
may backfire. The Lancet, 335(12 Feb), 558.
Metcalfe, S. D., S; Brougham, M; Moodie, P. (2003). PHARMAC measures
savings elsewhere to the health sector. New Zealand Medical Journal,
116(1170).
Minister of Health. (2007). Actioning Medicines New Zealand. Wellington:
Published in December 2007 by the Ministry of Health.
Ministry of Health. (2000). The NZ Public Health and Disability Act 2000.
Retrieved from
298